Logan Zemp (@LoganZemp) header
Logan Zemp (@LoganZemp) profile picture

Urologic Oncologist @Moffittnews via @MoffittGuONC & @UrologyAlberta | šŸ‡ØšŸ‡¦ | If you hang out at the barbershop long enough, you’ll eventually get a haircut

Tampa, FL
Joined February 2020
Photo by Logan Zemp (@LoganZemp)Photo by Logan Zemp (@LoganZemp)Photo by Logan Zemp (@LoganZemp)Photo by Logan Zemp (@LoganZemp)Photo by Logan Zemp (@LoganZemp)Photo by Logan Zemp (@LoganZemp)Photo by Logan Zemp (@LoganZemp)Photo by Logan Zemp (@LoganZemp)Photo by Logan Zemp (@LoganZemp)Photo by Logan Zemp (@LoganZemp)
Important change in the 2026 @AmerUrological NMIBC Guidelines: all high-grade Ta tumors are now classified as high-risk. This reduces a long-standing source of heterogeneity in the intermediate-risk group and should improve risk-appropriate treatment for patients, while creating cleaner, more meaningful populations for clinical trials. Great to see the evidence translate into practice. @IBCG_BladderCA @UrogerliMD @pjhensley11 @AmirHorowitz @mouwlab @spsutkaMD @shilpaonc @AndreaNecchi @LAUrology_NL @karima_oualla @PGrivasMDPhD @marigfern @SpiessPhilippe @UroCancerMD
Time to revisit something I’ve been saying for years: TaHG bladder cancer is not intermediate risk. The clinical outcomes, molecular biology ... all point in the same direction. Yet some frameworks allow < 3cm TaHG tumors to be downgraded into ā€œintermediate riskā€ alongside low-grade disease. That classification has real consequences for patients: • undertreatment • less rigorous surveillance • in some studies, these patients are even placed on observation as a supposedly appropriate ā€œcontrol arm.ā€ TaHG is high risk. 🧵 @BladderCancerUS @WorldBladderCan @IBCG_BladderCA
2
30
3
97
12,065
Congrats to our Urologic Oncology matched fellows! We excited for you to join the Moffitt team!
9
4
52
11,889
It was a fantastic surgical simulation opportunity with @MoffittGUOnc fellows, faculty members and other specialists from @MoffittNews today. The skills we honed will undoubtedly make a huge difference in the lives of many future patients.
1
1
8
631
Logan Zemp retweeted
Many @MoffittGUOnc faculty helped shape my career. Truly an honor to be visiting professor & share my academic journey w/ fellows. Phenomenal program w/ amazing ppl! Thanks @LoganZemp @MichaelPochMD @WadeJSexton9 @SpiessPhilippe @JulioPowSangMD Alice Yu Brandon Manley @UrogerliMD
3
59
2,124
Outcomes from 1027 pc-RPLNDs in NSGCT: • Residual mass size correlates with higher rates of teratoma and yolk sac tumor • Primary tumor histology associated with RPLND pathology šŸ”— doi.org/10.1016/j.annonc.202… @RichMatulewicz @SpiessPhilippe @SpiessPhilippe @drgaganprakash @LuisMedinaMD @npaesa @CMercinelli @dramandeeparora @CurtisPettaway1 @MDAndersonNews @MoffittNews @TataMemorial @MUSC_UroOnc @AmerUrological @UroOnc @SUO_YUO @CAU_URO @AndreaNecchi @orchidcancer @ERN_eUROGEN @EauPatient @JadChahoud
1
6
1
20
1,784
Day 1 on the new DV5 šŸ¤– at @MoffittNews today. Overall, the ergonomics, integrated insufflation, and laparoscope are significant upgrades. The minor downsides, changes to the bovie and vessel sealer sounds, were tolerable. Another great day in paradise! @IntuitiveSurg
2
27
926
Logan Zemp retweeted
Neoadjuvant EVP vs CisGem Now Out and WOW. #GU26 Path CR Rate Difference of 55.8% vs 32.5% is mind boggling, obviously leading to differences in EFS and OS... asco.org/abstracts-presentat…
15
1
61
6,458
New IBCG consensus: Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group (IBCG) Full text: authors.elsevier.com/a/1mf5C… @shilpaonc @AndreaNecchi @UrogerliMD @PGrivasMDPhD @FaltasLab @pjhensley11 @siadaneshmand @niyatilobo @mouwlab @karima_oualla @UroMoschini @BogdanaSchmidt @AStenzl @JoshMeeks @DrRosenbergMSK #OncSurgery
3
68
7
187
26,449
Exceptional meeting with close friends and thought leaders. All dedicated to advancing the fundamental knowledge and treatment standards of bladder cancer variant histologies. A huge unmet need. Thanks everyone for being part of this important effort.
Honored to present this morning at the joint IBCG–GSRGT Bladder Cancer Variant Histology Meeting in Tampa alongside Tom Flaig. We reviewed prior clinical trials in this space — highlighting lessons in eligibility, accrual, pathologic QA, and endpoints—and discussed how these insights can shape smarter study designs moving forward. Variant histology bladder cancer ≠ one disease. šŸ”¬ @LoganZemp @SpiessPhilippe @UroDocAsh @GdGrass @Prem_Ramkumar @AndreaNecchi @UrogerliMD @SethlernerMD @shilpaonc @siadaneshmand @TomFlaigMD @MassGenBrigham @IBCG_BladderCA #BladderCancer #CancerResearch #ClinicalTrials
2
2
2
22
2,264
Honored to present this morning at the joint IBCG–GSRGT Bladder Cancer Variant Histology Meeting in Tampa alongside Tom Flaig. We reviewed prior clinical trials in this space — highlighting lessons in eligibility, accrual, pathologic QA, and endpoints—and discussed how these insights can shape smarter study designs moving forward. Variant histology bladder cancer ≠ one disease. šŸ”¬ @LoganZemp @SpiessPhilippe @UroDocAsh @GdGrass @Prem_Ramkumar @AndreaNecchi @UrogerliMD @SethlernerMD @shilpaonc @siadaneshmand @TomFlaigMD @MassGenBrigham @IBCG_BladderCA #BladderCancer #CancerResearch #ClinicalTrials
2
5
3
21
5,589
Logan Zemp retweeted
In cisplatin-ineligible patients with muscle-invasive bladder cancer, enfortumab vedotin–pembrolizumab plus surgery led to better event-free survival (74.7%, vs. 39.4%) and overall survival (79.7%, vs. 63.1%) than surgery alone at 2 years. Full phase 3 KEYNOTE-905/EV-303 trial results: nej.md/4czl8sG Editorial: Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy nej.md/4twnv5T
3
117
19
281
78,711
Logan Zemp retweeted
#RoboUroOnc @CityofHopeSurg #Urology fellow, Dr. Ahmad Saeed Imam, @ImamOfUrology, presenting multidisciplinary research efforts at #WSAUA25 @auawest in #prostatecancer & #ilealureter creation. @SalvadorjcMD @BYuhMD @WesleyYipMD @arafflemd @montypal @COHurol @ClaytonLauMD
1
9
32
1,899
Proud of our @USFUrology stars — Dr. Joe Balbona, Dr. Alyssa Biollota & Dr. Tyler Cook — finishing their @MoffittNews rotation! Until next time — the future of urology is in great hands. šŸ‘ @AmerUrological @UrologyMatch
2
15
925
🚨Publication alert in @UrolOncol! National complication and cost burden of transurethral resection of bladder tumor for bladder cancer Click to read the articleā–¶ļø bit.ly/3JmhHt7
1
12
1
39
8,662
šŸŽ‰ The @AmerUrological and the UCF are excited to recognize 12 researchers as recipients of the 2025 Urology Care Foundation Research Scholar Awards! This program has invested over $30 million to support over 675 Research Scholars! Click to learn more šŸ‘‰ bit.ly/48G1Iyn
3
7
6
31
15,104
A very sad day learning that a giant in urology passed, Donald G. Skinner MD His impact was profound. His commitment to surgical excellence was only matched by his devotion to pt care and teaching. Simply the best mentor, colleague and friend RIP Boss @UroOnc @AmerUrological
15
30
6
175
29,315
Congrats @GabrielleYanke2 @BMoraGarijo , Dr. Syed Rahman on matching with Moffitt GU Onc. we’re super excited you’ll be joining us next year!!
2
6
43
2,654
Couldn’t agree more. @LeileiXiaUro found similar results in updated cohort 2010-2018 cT1 + LVI compared to T2 w/o LVI associated with significantly worse OS HR 1.63. @PennUrology @tbivala1
LVI is tough. With our improved management and therapies I am generally aggressive in promoting bladder sparing for NMIBC - but this gives pause: T1 with LVI had higher node positivity rates than MIBC without LVI, at least in NCDB 2004-2014.. Need large granular series that include more variables (blue light, presence of LVI at re-TURBT) and contemporary agents (especially immune) to get more answers pubmed.ncbi.nlm.nih.gov/3029…
2
5
30
2,633
Logan Zemp retweeted
Bladder cancer session #JSMO25 - Longer term follow up for EVP showing 34 months median OS and 2 year median duration of response. Adverse events different from standard chemotherapy @uromigosjapan
1
8
1
61
3,813
Not only a great surgeon & the @SUO_YUO @MoffittGUOnc fellowship director, but an innovative researcher. Congrats on your TIL therapy trial Dr @michael_poch.
Urologist Michael Poch, MD (@Michael_Poch) shares insights on an innovative trial exploring TIL therapy for bladder cancer. This study is pushing boundaries and applying #TILtherapy to a new type of cancer. Read more: bit.ly/3Xfq3pA #CancerResearch
1
20
1,745